Transduction of dendritic cells with Bcl-x(L) increases their resistance to prostate cancer-induced apoptosis and antitumor effect in mice

Journal of Immunology

Volumn 165, Issue 4, 2000, Pages 1956-1964

  Pirtskhalaishvili, G ^a   Shurin, G V ^a   Gambotto, A ^a   Esche, C ^a   Wahl, M ^a   Yurkovetsky, Z R ^a   Robbins, P D ^a   Shurin, M R ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNOLOGY; DENDRITIC CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA;

EID: 0034662858     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.4.1956     Document Type: Article

References (60)

1. Cancer statistics, 1999
2. Implication of cell kinetic changes during the progression of human prostatic cancer
3. MHC class I and II expression in prostate carcinoma and modulation by interferon-α and γ
4. Impaired expression and function of signal-transducing ζ chains in peripheral T cells and natural killer cells in patients with prostate cancer
5. Report of immune monitoring of prostate cancer patients undergoing T- cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA)
6. Quantitative alterations in cutaneous Langerhans cells during the evolution of malignant melanoma of the skin
7. Modulation of apoptosis signaling pathways and cell cycle regulation
8. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution
9. Dendritic cells presenting tumor antigen
10. Distribution of Langerhans cells and HLA class II molecules in prostatic carcinomas of different histopathological grade
11. Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer
12. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen
13. Dendritic cell-based immunotherapy of prostate cancer
14. Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins
15. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes
16. Interleukin-12 synergizes with interleukin-3 and steel factor to enhance recovery of murine hemopoietic stem cells in liquid culture
17. Dual stimulatory and inhibitory effect of NK cell stimulatory factor/IL-12 on human hematopoiesis
18. Ultraviolet light-induced immune tolerance is mediated via the Fas/Fas-ligand system
19. Tumor's other immune targets: Dendritic cells
20. Antitumor and antimetastatic activity of interleukin 12 against murine tumors
21. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production
22. Role of NK and T cells in IL-12-induced anti-tumor response against hepatic colon carcinoma
23. Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12
24. Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models
25. Antitumor activities of IL-12 and mechanisms of action
26. Interleukin-12 and FLT3 ligand differentially regulate dendropoiesis in mice
27. Bcl-2 proteins: Regulators of apoptosis or of mitochondrial homeostasis?
28. Control of apoptosis in hematopoiesis and leukemia by cytokines, tumor suppressor and oncogenes
29. Self-reactive B lymphocytes overexpressing Bcl-xL escape negative selection and are tolerized by clonal anergy and receptor editing
30. FLT3 ligand induces the generation of functionally active dendritic cells in mice
31. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics
32. Construction of adenovirus vectors through Cre-lox recombination
33. FACS-optimized mutants of the green fluorescent protein (GFP)
34. The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors
35. Lymphoproliferation disorder in mice explained by defects in Fas that mediates apoptosis
36. IL-12-engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo
37. Vaccination of patients with B-cell lymphoma using autologous antigen pulsed dendritic cells
38. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors
39. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
40. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro
41. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation
42. Interleukin-12 production by dendritic cells: The role of CD40-CD40L interactions in Th1 T-cell responses
43. Antitumor effect of CD40 ligand: Elicitation of local and systemic antitumor responses by 1L-12 and B7
44. IL-12 up-regulates CD40 ligand (CD154) expression on human T cells
45. Mechanisms of 1FN-γ induction by natural killer cell stimulatory factor (NKSF/IL-12): Role of transcription and mRNA stability in the synergistic interaction between NKSF and IL-2
46. Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells
47. + lymphocytes in the initiation of class I-restricted reactivity to a tumor/self peptide
48. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma
49. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: Suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model
50. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12
51. Inactivation of E2a in recombinant adenovirus improves the prospect for gene therapy in cystic fibrosis
52. Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination
53. Bcl-2 prevents nitric oxide-mediated apoptosis and poly(ADP-ribose) polymerase cleavage
54. Interaction and regulation of subcellular localization of CED-4 by CED-9
55. Interaction of CED-4 with CED-3 and CED-9: A molecular framework for cell death
56. Interaction between the C. elegans cell-death regulators CED-9 and CED-4
57. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax
58. CD40 ligation counteracts Fas-induced apoptosis of human dendritic cells
59. Fas counter-attack: The best form of tumor defense?